Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma
Authors:
- Raed Awadh AlshammariRaed Awadh Alshammari
- Samuel M. RubinsteinSamuel M. Rubinstein
- Eric Farber-EgerEric Farber-Eger
- Lauren Lee ShafferLauren Lee Shaffer
- Marwa TantawyMarwa Tantawy
- Mohammed E. AlomarMohammed E. Alomar
- Quinn S. WellsQuinn S. Wells
- Daniel LenihanDaniel Lenihan
- Robert F. CornellRobert F. Cornell
- Kenneth H. ShainKenneth H. Shain
- Rachid C. BazRachid C. Baz
- Yan GongYan Gong
Open Access
Abstract
Background/Objectives: Carfilzomib (CFZ) and bortezomib (BTZ) are proteasome inhibitors used as the first-line therapy for relapsed or refractory multiple myeloma (MM) but are associated with cardiovascular adverse events (CVAEs). This study aims to identify differentially methylated positions (DMPs) and regions (DMRs), and enriched pathways associated with CVAEs related to CFZ or BTZ-based treatment. Methods: Baseline germline DNA methylation profiles from 79 MM patients (49 on CFZ and 30 on BTZ) in the Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy (PROTECT) were analyzed. Epigenome-wide analyses were performed within each group, followed by meta-analyses to identify signals common to CVAEs associated with both medicines. Results: Four DMPs were significantly associated with CFZ-CVAEs, including cg15144237 within ENSG00000224400 (p = 9.45 × 10−10), cg00927646 within TBX3 (p = 9.78 × 10−8), and cg10965131 within WDR86 (p = 1.00 × 10−7). One DMR was identified in the FAM166B region (p = 5.46 × 10−7). There was no evidence of any DMPs in BTZ-treated patients, however two DMPs and one DMR reached a suggestive level of significance (p < 1.00 × 10−5): cg09666417 in DNAJC18 (p = 3.41 × 10−7) and cg12987761 in USP18 (p = 5.00 × 10−7), and a DMR mapped to the WDR86/WDR86-AS1 region (p = 8.11 × 10−8). Meta-analysis did not find any significant DMPs, with the top CpG being cg17933807 in GNL2 (p = 7.38 × 10−5). Pathway enrichment analyses identified peroxisome, MAPK, Rap1, adherens junction, phospholipase D, autophagy, and aldosterone-related pathways to be implicated in CVAEs. Conclusions: Our study identified distinct DMPs, DMRs, and pathways enrichment associated with CVAE, suggesting epigenetic contributors to CVAEs and supporting the need for larger validation studies.Keywords
All Related Versions
Funding Information
- National Institute of Health (R01HL151659)
This publication has 57 references indexed in Scilit:
- GLN2 as a key biomarker and therapeutic target: evidence from a comprehensive pan-cancer study using molecular, functional, and bioinformatic analysesDiscover Oncology, 2024
- The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicityBasic Research in Cardiology, 2024
- Blood DNA Methylation and Incident Coronary Heart DiseaseJAMA Cardiology, 2021
- Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and PreventionCurrent Treatment Options in Cardiovascular Medicine, 2018
- Carfilzomib-Associated Cardiovascular Adverse EventsJAMA Oncology, 2018
- The proteasome and proteasome inhibitors in multiple myelomaCancer and Metastasis Reviews, 2017
- Ixazomib: First Global ApprovalDrugs, 2016
- Proteasome inhibitorsBiochemical Pharmacology, 2015
- Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple MyelomaJournal of Cardiac Failure, 2015
- Peroxisomes and oxidative stressBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2006